MDx revenues increased 3 percent to $158.0 million, but excluding non-recurring royalty revenue in the prior-year period, MDx revenues increased 10 percent.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
Total revenues were down due to lower assay revenues, which shrank 11 percent from a year ago. Sample-to-answer molecular product revenues grew 15 percent.
The company said it saw the biggest revenue growth in its instruments business, which gained 32 percent year over year.
After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.
The company missed analysts' consensus estimate for revenues but beat Wall Street expectations on the bottom line.
The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.
The company reported $5.92 billion in revenues for the quarter, driven by growth across its four business segments.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.